VECTURA
DEAD

Serial Number

79202821

Owner

Vectura Limited

Attorney

Molly B. Markley

Filing Date

Nov 25, 2016

Add to watchlist:

No watchlists yet
View on USPTO

VECTURA Trademark

Serial Number: 79202821 • Registration: 5337619

VECTURA is a trademark filed by Vectura Limited on November 25, 2016. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Vectura Limited (17 trademarks)

1 Prospect West
Chippenham, Wiltshire SN146FH , GB

Entity Type: 99

Trademark Details

Filing Date

November 25, 2016

Registration Date

November 21, 2017

Published for Opposition

September 5, 2017

Cancellation Date

June 7, 2024

Goods & Services

Pharmaceutical and biological preparations for medical purpose, namely for the treatment of diseases or conditions of the respiratory system; pharmaceutical and biological preparations for medical purposes, namely the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical and biological preparations for medical purposes, namely for the alleviation or prevention of pain or inflammation; pharmaceutical and biological preparations for medical purposes, namely, powders for asthma inhalers; pharmaceutical and biological preparations for medical purposes, namely, powders for transdermal injection for the alleviation or prevention of pain, for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposes, namely for oral ingestion for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genitourinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposes, namely for topical administration for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purpose, namely, medicaments for inhalation therapy; pharmaceutical and biological preparations for medical purposes, namely, pulmonary delivery compositions for use in facilitating the inhalation of pharmaceuticals, namely, drug delivery agents consisting of compounds that facilitate delivery by inhalation of a wide range of pharmaceuticals; pharmaceutical and biological preparations for medical purpose, namely medicaments for the treatment of erectile dysfunction, medicaments for the treatment of chronic obstructive pulmonary disease, medicaments for the treatment of premature ejaculation, medicaments for the treatment of cystic fibrosis, medicaments for the treatment of female sexual dysfunction, medicaments for the treatment of migraines, and medicaments for the treatment of asthma

Drug delivery devices, namely, drug delivery systems; inhalers for medical use; metered dose inhalers for medical use; active dry powder inhalers for medical use; passive dry powder inhalers for medical use; nebulisers for respiration therapy; respirators for artificial respiration; parts and fittings for all the aforesaid goods

Scientific research, development, design, analysis, testing and investigation relating to medical preparations and drug delivery devices; medical research; research relating to drug delivery devices; research relating to drug formulation; pharmaceutical development; preparation and formulation of pharmaceuticals; device and product testing namely device and product testing of drug delivery devices and medical preparations

Filing History

TOTAL INVALIDATION PROCESSED BY THE IB
May 17, 2025 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Apr 28, 2025 INTS
INVALIDATION PROCESSED
Apr 28, 2025 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Feb 7, 2025 INTR
CANCELLED SECTION 71
Jun 7, 2024 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Dec 22, 2023 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 21, 2022 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Oct 8, 2022 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 27, 2018 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Mar 3, 2018 FICS
FINAL DISPOSITION PROCESSED
Mar 2, 2018 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 21, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 21, 2017 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 5, 2017 NPUB
PUBLISHED FOR OPPOSITION
Sep 5, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 16, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 23, 2017 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 21, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 20, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 20, 2017 TROA
REFUSAL PROCESSED BY IB
Apr 2, 2017 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 16, 2017 RFCS
REFUSAL PROCESSED BY MPU
Mar 16, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 16, 2017 RFCR
NON-FINAL ACTION WRITTEN
Mar 15, 2017 CNRT
APPLICATION FILING RECEIPT MAILED
Mar 14, 2017 MAFR
ASSIGNED TO EXAMINER
Mar 11, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 10, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 9, 2017 REPR